← Back

Delivery Systems that “De-Target” the Liver and Macrophages

New delivery mechanisms are needed to target the desired tissues and avoid uptake by hepatocytes and macrophages. Off-target uptake necessitates higher dosing, increasing toxicity risks.

R&D Gaps (1)

Current in-vivo delivery systems (viral vectors, nanoparticles, microchips) face challenges such as off-target accumulation and inefficiency, particularly in delivering therapies to the brain. Novel delivery approaches are needed to improve targeting and performance.